We are live on ! Find out more
EBS icon

Emergent Biosolutions
EBS

238 hedge funds and large institutions have $1.88B invested in Emergent Biosolutions in 2017 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 104 increasing their positions, 60 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

373% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 11

73% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 60

25% more capital invested

Capital invested by funds: $1.5B → $1.88B (+$378M)

20% more funds holding

Funds holding: 198 → 238 (+40)

7.58% more ownership

Funds ownership: 90% → 97.58% (+7.6%)

47% less call options, than puts

Call options by funds: $684K | Put options by funds: $1.29M

Holders
238
Holders Change
+40
Holders Change %
+20.2%
% of All Funds
5.4%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
52
Increased
104
Reduced
60
Closed
11
Calls
$684K
Puts
$1.29M
Net Calls
-$609K
Net Calls Change
-$1.63M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$24.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$18.2M
3
AAMU
Amundi Asset Management US
Massachusetts
+$14.9M
4
O
OppenheimerFunds
New York
+$13.6M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$11.1M

Top Sellers

Rank Fund Capital Flow
1
GT
Glenmede Trust
Pennsylvania
-$22.3M
2
Fidelity International
Fidelity International
Bermuda
-$11.2M
3
Charles Schwab
Charles Schwab
California
-$6.03M
4
GAM
Gotham Asset Management
New York
-$4.93M
5
Bank of America
Bank of America
North Carolina
-$4.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAMU
26
Amundi Asset Management US
Massachusetts
$16.4M +$14.9M +353,957 New
GC
27
Guggenheim Capital
Illinois
$15.8M -$1.07M -25,359 -7%
AQR Capital Management
28
AQR Capital Management
Connecticut
$15.5M +$2.86M +68,050 +26%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$15.4M +$107K +2,536 +0.8%
O
30
OppenheimerFunds
New York
$15.4M +$13.6M +321,918 +3,272%
MCM
31
Matarin Capital Management
New York
$15.1M +$619K +14,705 +5%
Principal Financial Group
32
Principal Financial Group
Iowa
$13.2M +$833K +19,791 +7%
Ameriprise
33
Ameriprise
Minnesota
$13M +$99.9K +2,374 +0.9%
Fidelity International
34
Fidelity International
Bermuda
$12.5M -$11.2M -267,258 -50%
Morgan Stanley
35
Morgan Stanley
New York
$12.3M +$4.63M +110,079 +71%
NAP
36
New Amsterdam Partners
New York
$12.1M +$4.13M +98,034 +60%
Deutsche Bank
37
Deutsche Bank
Germany
$11.8M +$3.47M +82,454 +48%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$11.4M -$2.18M -51,702 -17%
KCM
39
Kennedy Capital Management
Missouri
$10.4M -$402K -9,541 -4%
PPA
40
Parametric Portfolio Associates
Washington
$10.3M +$2.52M +59,821 +37%
Fuller & Thaler Asset Management
41
Fuller & Thaler Asset Management
California
$10.3M +$9.33M +221,640 New
Bank of America
42
Bank of America
North Carolina
$9.69M -$4.85M -115,269 -36%
Jacobs Levy Equity Management
43
Jacobs Levy Equity Management
New Jersey
$8.7M +$961K +22,830 +14%
TCIM
44
TIAA CREF Investment Management
New York
$7.83M +$3.41M +81,125 +93%
EAM
45
Eagle Asset Management
Florida
$6.67M -$4.62M -109,771 -43%
PAM
46
Panagora Asset Management
Massachusetts
$6.18M +$5.14M +122,079 +1,123%
Wells Fargo
47
Wells Fargo
California
$6.15M +$1.73M +41,169 +45%
BA
48
Boston Advisors
Massachusetts
$6.15M +$4.96M +117,867 +815%
MOACM
49
Mutual of America Capital Management
New York
$6.07M +$140K +3,325 +3%
NI
50
Numeric Investors
Massachusetts
$5.85M +$4.88M +115,900 +1,171%
1
2
3 4 5

EBS Hedge Fund Activity: Q4 2017 in Review

238 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2017, worth a combined $1.88B — up 25% from $1.5B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new EBS positions and 11 closed out — a net gain of 41 holders — while 104 added to existing stakes and 60 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $24.3M. The largest seller was Glenmede Trust, cutting an estimated $22.3M.

  • 238 institutional investors held Emergent Biosolutions (EBS) as of Q4 2017, up from 198 in Q3 2017.
  • Funds reported $1.88B of Emergent Biosolutions stock for Q4 2017, up 25% quarter-over-quarter.
  • 52 funds opened new Emergent Biosolutions positions in Q4 2017 and 11 closed out, a net change of +41 holders.
  • The largest Emergent Biosolutions buyer in Q4 2017 was Goldman Sachs, an estimated $24.3M added.
  • The largest Emergent Biosolutions seller in Q4 2017 was Glenmede Trust, an estimated $22.3M sold.

Based on aggregated 13F filings for Q4 2017.